Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Inclusion Criteria: * Male or female subjects aged ≥18 years * Histologically or cytologically confirmed, locally advanced or metastatic solid cancers known to express mesothelin on the tumor cell surface (e.g. predominantly epithelial \[\>=50% tumor component\] pleural or peritoneal mesothelioma, epithelial ovarian cancer \[including the fallopian tube or primary peritoneal\], adenocarcinoma of the pancreas, triple-negative adenocarcinoma of the breast, non-small-cell adenocarcinoma of the lung, endometrial cancer, serous uterine cancer, gastric cancer \[including the gastro-esophageal junction\], colon cancer, cholangiocarcinoma, thymic carcinoma, etc.). Subjects with resected primary cancers who have documented metastases or local recurrence are eligible. * Subjects must have no standard therapy available, or have actively refused standard therapy * Subjects must meet the criteria for one of the 4 treatment groups: * Group A: Adequate hepatic and renal function (controls) * Group B: Mild hepatic impairment, i.e. Grade A according to the Child-Pugh Classification (total score of 5 or 6) and adequate renal function * Group C: Moderate hepatic impairment, i.e. Grade B according to the Child-Pugh Classification (total score of 7, 8 or 9) and adequate renal function * Group D: Moderate renal impairment, i.e. eGFR (estimated glomerular filtration rate) \<60 and ≥30 mL/min per 1.73 m\*2 and hepatic function better than, or equal to mild impairment according to the Child…